10月31日，毕得医药获德邦证券买入评级，近一个月毕得医药获得4份研报关注。
研报预计公司2023-2025年实现归母净利润1.8/2.5/3.3亿元，对应当前股价PE33X/25X/18X。研报认为，公司是国内分子砌块行业的龙头企业，具备“多快好省”优势，且公司海外市场不断取得突破，看好公司业务成长性。
风险提示：公司存货余额较高及存货管理内部控制相关风险；境外销售不及预期的风险；市场竞争加剧的风险；业务拓展不及预期的风险。
- Headlines
- 毕得医药获德邦证券买入评级，预测2023年归母净利润1.8亿元
毕得医药获德邦证券买入评级，预测2023年归母净利润1.8亿元
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Hot News
Updated
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.